Citations

Showing 10 of 108162 citations.

Cognitive outcomes in patients with low-grade glioma
Brown, Paul D. , Trifiletti, Daniel M.

Mayo Clinic

Neuro-Oncology | February 8, 2021 | Volume: 23 | Issue: 5 | Pages: 709-710

10.1093/neuonc/noab033 | PMID 33704493 Get It

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Armstrong, Deborah K. , Alvarez, Ronald D. , Barroilhet, Lisa , Chen, Lee-may, Cristea, Mihaela , Eisenhauer, Eric , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Karam, Amer , Konecny, Gottfried E. , Mahdi, Haider , McHale, Michael , Miller, David S. , O’Malley, David M. , Percac‐Lima, Sanja , Ratner, Elena , Remmenga, Steven W., Vargas, Roberto , Werner, Theresa L. , Zsíros, Emese , Burns, Jennifer L. , Engh, Anita M. , Miller, David S , O'Malley, David M , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , DeRosa, Maria, Gershenson, David M. , Grisham, Rachel Nicole , Leath, Charles A , Liu, Joyce F. , Martin, Lainie P. , Matei, Daniela , McLean, Karen

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 8, 2021 | Volume: 19 | Issue: 2 | Pages: 191-226

10.6004/jnccn.2021.0007 | PMID 33545690 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country’s fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypes─high-grade serous and grade 2/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cord-stromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.
Non-canonical IDH Mutation Frequency in IDH1-R132H-Negative Glioblastoma Patients Older Than 54 Years
Pryzbylski, Amber L, Kollmeyer, Thomas M. , Praska, Corinne , Jentoft, Mark E. , Halling, Kevin C. , Zheng, Gang , DiGuardo, Margaret , Kipp, Benjamin R. , Jenkins, Robert B. , Praska, Corinne E, DiGuardo, Margaret A , Kollmeyer, Thomas , Pryzbylski, Amber , Raghunathan, Aditya , Giannini, Caterina , Vaubel, Rachael A. , Ida, Cristiane M.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | February 8, 2021 | Volume: 80 | Issue: 8 | Pages: 804-806

10.1093/jnen/nlab004 | PMID 33550363 Get It

Long‐term lithium therapy and risk of chronic kidney disease in bipolar disorder: A historical cohort study
Pahwa, Mehak , Joseph, Boney , Núñez, Nicolás A. , Jenkins, Gregory D. , Colby, Colin , Moore, Katherine M. , Betcher, Hannah K. , Özerdem, Ayşegül , Cuéllar‐Barboza, Alfredo B. , Frye, Mark A. , Singh, Balwinder , Colby, Colin L., Cuellar-Barboza, Alfredo , Biernacka, Joanna , Singh, Balwinder , Joseph, Boney , Ozerdem, Aysegul , Kashani, Kianoush , Veldić, Marin , McElroy, Susan L. , Biernacka, Joanna M.

Mayo Clinic

Bipolar Disorders | February 8, 2021 | Volume: 23 | Issue: 7 | Pages: 715-723

10.1111/bdi.13052 | PMID 33548063 Get It

AbstractAimsLong‐term lithium therapy (LTLT) has been associated with kidney insufficiency in bipolar disorder (BD). We aimed to investigate the risk factors of chronic kidney disease (CKD) development and progression among BD patients receiving LTLT.MethodsWe included adult patients with BD on LTLT (≥1 year) who were enrolled in the Mayo Clinic Bipolar Biobank, Rochester, Minnesota. We reviewed electronic medical records to extract information related to lithium therapy and kidney‐related data to assess changes in the estimated glomerular filtration rate (eGFR). CKD severity was assessed based on eGFR.ResultsAmong 154 patients who received LTLT, 41 patients (27%) developed CKD, of whom 20 (49%) patients continued lithium (continuers) and 19 (46%) discontinued it (discontinuers). The median time to stage 3 CKD development was 21.7 years from the start of Li treatment. Type‐2 diabetes mellitus and benzodiazepine use were independent predictors for CKD development in the survival analysis, after controlling for age. The subsequent CKD progression rate did not differ between continuers and discontinuers (mean GFR 48.6 vs. 44.1, p = 0.13) at the end of follow‐up duration (mean duration: 3.5 ± 4.4 years for continuers and 4.9 ± 5.3 years for discontinuers).ConclusionCKD was observed in one fourth of patients with BD receiving LTLT. There was no significant difference in the progression of CKD among Li continuers versus discontinuers, at the mean follow‐up duration of 4.2 years, after the CKD diagnosis. Progression of CKD could be influenced by existing comorbidities and may not necessarily be due to lithium alone.
Identification of Genetic Variants Regulating the Abundance of Clinically Relevant Plasma Proteins using the Diversity Outbred Mouse Model
Philtjens, Stéphanie , Kim, Hyewon , Kim, Jungsu , Kim, Jungsu , Acri, Dominic J. , Kim, Byung-Wook

Mayo Clinic

No container title available | February 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-171899/v1 Get It

Abstract Background: Levels of plasma proteins are under control of environmental and genetic factors. To use plasma proteins in biomarker studies, we need to understand how genetic modifiers influence their abundance. Although there has been expression quantitative trait loci (eQTL) studies on a few limited numbers of proteins, the effect of genetic variants on the levels of multiple plasma proteins still warrants more systematic investigation.Results: To identify genetic modifiers that influence the levels of clinically relevant plasma proteins, we performed protein quantitative trait locus (pQTL) mapping on the 92 proteins present in the Olink Mouse Exploratory Panel using the Diversity Outbred (DO) mouse population. We identified 12 significant pQTL that were located in cis and 6 that were in trans. Among them, we discovered that the presence of coding variants in the gene encoding for the Aryl Hydrocarbon Receptor (Ahr) had a significant effect on its abundance in plasma. Most interestingly, we identified variants in the Regulatory Factor X1 (Rfx1) gene that influence the abundance of the IL-17A protein in plasma.Conclusion: Our study reports an innovative pipeline for the identification of genetic modifiers that may be targeted for drug development.
Comparison of Endocrine Outcomes Following Proton and Photon Radiotherapy in Children With Medulloblastoma 
Aldrich, Kathleen Danielle , Bielamowicz, Kevin , Sonabend, Rona , Mahajan, Anita , Chintagumpala, Murali , Okcu, M. Fatih , Horne, Vincent E. , Scheurer, Michael E. , Paulino, Arnold C. , Brown, Austin L.

Mayo Clinic

No container title available | February 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-171471/v1 Get It

Abstract Background: Endocrine deficiencies are common following craniospinal irradiation (CSI) in children with brain tumors, but empirical data comparing outcomes following proton (PRT) and photon radiation therapy (XRT) are limited. Methods: This retrospective chart review compared the incidence of hypothyroidism, growth hormone deficiency (GHD), and adrenal insufficiency (AI) in patients with medulloblastoma treated with XRT and PRT between 1997 and 2016. All patients received CSI and had routine endocrine screening labs to evaluate for thyroid dysfunction, GHD, and AI. We used proportional hazards regression to calculate hazard ratios (HR) and 95% confidence intervals (CI) comparing the development of hypothyroidism, AI, and GHD between radiation modalities, adjusting for age at diagnosis, sex, race/ethnicity, and CSI dose.Results: We identified 118 patients with medulloblastoma who were followed for a median of 5.6 years from the end of radiotherapy. Thirty-five (31%) patients developed hypothyroidism, 71 (66%) GHD, and 20 (18%) AI. Compared to PRT, XRT was associated with a higher incidence of primary (28% vs. 6%; HR=4.61, 95% CI 1.2-17.7, p=0.03) and central hypothyroidism (33% vs. 9%; HR 2.35 (0.8-6.8, p=0.12). GHD and AI incidence rates were similar between the groups. Conclusions: Primary and central hypothyroidism occur less often after PRT CSI, compared to XRT CSI. This suggests that the thyroid and pituitary glands receive less radiation after spine and posterior fossa boost RT, respectively, using PRT.
Isolated Maternal Hypothyroxinemia Is Associated with Preterm Delivery
Toloza, Freddy J.K. , Maraka, Spyridoula

Mayo Clinic

Clinical Thyroidology | February 8, 2021 | Volume: 33 | Issue: 2 | Pages: 80-82

10.1089/ct.2021;33.80-82 Get It

Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show?
Candow, Darren G. , Kreider, Richard B. , Rawson, Eric S., VanDusseldorp, Trisha A. , Willoughby, Darryn S. , Ziegenfuss, Tim N. , Antonio, Jose , Kreider, Richard B , António, José , Forbes, Scott C. , Gualano, Bruno , Jagim, Andrew R. , Smith‐Ryan, Abbie E.

Mayo Clinic

Journal of the International Society of Sports Nutrition | February 8, 2021 | Volume: 18 | Issue: 1 | Pages: No page available

10.1186/s12970-021-00412-w | PMID 33557850 Get It

HER-2 Amplification in Uterine Serous Carcinoma and Serous Endometrial Intraepithelial Carcinoma
Banet, Natalie , Shahi, Maryam , Batista, Denise , Yonescu, Raluca, Fader, Amanda N. , Cimino‐Mathews, Ashley , Tanner, Edward J.

Mayo Clinic

American Journal of Surgical Pathology | February 8, 2021 | Volume: 45 | Issue: 5 | Pages: 708-715

10.1097/pas.0000000000001682 | PMID 33739786 Get It

Human epidermal growth factor receptor 2 (HER-2) targeted therapy shows promising results in HER-2-positive uterine serous carcinoma (USC). HER-2 scoring criteria for USC and its associated noninvasive lesion, serous endometrial intraepithelial carcinoma (SEIC), are not well-established. Here, we compare the breast and gastric (GI) HER-2 immunohistochemistry (IHC) scoring criteria for HER-2 with HER-2/neu fluorescence in situ hybridization (FISH) in 68 tumors (17 USC with SEIC, 30 USC, 18 SEIC, 3 metastatic USC). The majority (97%) of lesions displayed intratumoral HER-2 IHC heterogeneity. Breast or GI IHC scoring criteria were performed equivalently. The breast and GI IHC criteria classified 51% and 47% USC as HER-2 negative (IHC 0/1+), 40% and 45% as equivocal (IHC 2+), and 9% each as HER-2 positive (IHC 3+). A quarter of USC classified as HER-2 negative or positive with the breast (25%, n=7/28) or GI IHC criteria (23%, n=6/26) was discordant by FISH. Specifically, 13% to 14% of IHC 0/1+ USC were FISH amplified; 50% of IHC 3+ USC were FISH negative. The majority (77% to 83%) of SEIC were HER-2 IHC 0/1+, and no SEIC was HER-2 IHC 3+. A minority (4% to 7%) of IHC 0/1+ SEIC were FISH positive. Discordant HER-2 status was observed between half (47%,bn=7/15) of synchronous SEIC and USC. In conclusion, USC displays HER-2 intratumoral heterogeneity, a high IHC/FISH discordance rate, and variation in HER-2 status between the SEIC and invasive components. Caution is required when evaluating HER-2 in small biopsies, which should be repeated on excisions. Both IHC and FISH should be performed on USC until clinical trials correlate HER-2 status with clinical response to HER-2-targeted therapy.
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Nowakowski, Grzegorz S. , Hong, Fangxin , Scott, David W. , Macon, William R. , King, Rebecca L. , Wagner‐Johnston, Nina D. , Wade, James L. , Nagargoje, Gauri G., Reynolds, Chris, Cohen, Jonathon B. , Amengual, Jennifer E. , Richards, Kristy L. , Little, Richard F. , Leonard, John P. , Friedberg, Jonathan W. , Kostakoglu, Lale , Wade, James L , Cohen, Jonathon B , Khan, Nadia , Amengual, Jennifer E , Little, Richard F , Kostakoglu, Lale , Kahl, Brad S , Witzig, T.E. , Scott, David W , Hong, Fangxin , Habermann, Thomas M. , Casulo, Carla , Khan, Nadia , Kahl, Brad S. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | February 8, 2021 | Volume: 39 | Issue: 12 | Pages: 1329-1338

10.1200/jco.20.01375 | PMID 33555941 Get It

PURPOSE Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, particularly in the activated B-cell–like (ABC) subtype. Eastern Cooperative Oncology Group (ECOG)-ACRIN trial E1412 was a randomized phase II study comparing R2CHOP versus R-CHOP in untreated DLBCL. PATIENTS AND METHODS Patients with newly diagnosed DLBCL, stage II bulky-IV disease, International Prognostic Index (IPI) ≥ 2, and ECOG performance status ≤ 2 were eligible and randomly assigned 1:1 to R2CHOP versus R-CHOP for six cycles. Tumors were analyzed using the NanoString Lymph2Cx for cell of origin. The primary end point was progression-free survival (PFS) in all patients with the co-primary end point of PFS in ABC-DLBCL. Secondary end points included overall response rate (ORR), complete response (CR) rate, and overall survival (OS). RESULTS Three hundred forty-nine patients were enrolled; 280 patients (145 R2CHOP and 135 R-CHOP) were evaluable: 94 were ABC-DLBCL, 122 germinal center B-cell–like-DLBCL, 18 unclassifiable, and 46 unknowns. Baseline characteristics were well-balanced between arms, and the median age was 66 (range, 24-92); 70% of patients had stage IV disease; 34%, 43%, and 24% had IPI 2, 3, and 4 or 5, respectively. Myelosuppression was more common in the R2CHOP arm. The ORR and CR rate were 92% and 68% in R-CHOP and 97% ( P = .06) and 73% ( P = .43) in the R2CHOP arm, respectively. The median follow-up was 3.0 years; R2CHOP was associated with a 34% reduction in risk of progression or death versus R-CHOP (hazard ratio [HR], 0.66 95% CI, 0.43 to 1.01) and 3-year PFS of 73% versus 61%, one-sided P = .03, and an improvement in OS (83% and 75% at 3 years; HR, 0.67; one-sided P = .05). The PFS HR for R2CHOP was 0.67 for ABC-DLBCL, one-sided P = .1. CONCLUSION In this signal-seeking study, the addition of lenalidomide to R-CHOP (R2CHOP) improved outcomes in newly diagnosed DLBCL including patients with ABC-DLBCL.